Stocktoria
Chemours Co CC
NYSE · XNYS · stock · Chemicals & Allied Products · website · IPO 2015-06-19
Chemours Co financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.8B | $5.8B | $6.1B | $6.8B | $6.3B |
| Gross profit | $902.0M | $1.1B | $1.3B | $1.6B | $1.4B |
| R&D expense | $108.0M | $109.0M | $108.0M | $118.0M | $107.0M |
| SG&A expense | $799.0M | $598.0M | $1.3B | $710.0M | $592.0M |
| Interest expense | $269.0M | $263.0M | $208.0M | $163.0M | $185.0M |
| Income tax | $109.0M | $37.0M | -$66.0M | $163.0M | $68.0M |
| Net income | -$386.0M | $69.0M | -$253.0M | $578.0M | $608.0M |
| EPS (diluted) | $-2.57 | $0.46 | $-1.70 | $3.65 | $3.60 |
| Operating cash flow | $264.0M | -$633.0M | $556.0M | $755.0M | $814.0M |
| Free cash flow | $51.0M | -$993.0M | $186.0M | $448.0M | $537.0M |
| Cash & equivalents | $670.0M | $713.0M | $1.2B | $1.1B | $1.5B |
| Inventory | $1.6B | $1.5B | $1.3B | $1.4B | $1.1B |
| Total assets | $7.4B | $7.5B | $8.2B | $7.6B | $7.5B |
| Total liabilities | $7.1B | $6.9B | $7.5B | $6.5B | $6.5B |
| Shareholders' equity | $251.0M | $572.0M | $723.0M | $1.1B | $1.1B |
Source: SEC EDGAR filings · CIK 0001627223 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.